{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T10:55:17Z","timestamp":1759056917870,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30870841","30972721"],"award-info":[{"award-number":["30870841","30972721"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jns.2011.09.037","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T17:45:30Z","timestamp":1318873530000},"page":"27-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Different molecular expression in thymoma with ocular or generalized myasthenia gravis"],"prefix":"10.1016","volume":"313","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2011.09.037_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","article-title":"Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients","volume":"273","author":"Hong","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2011.09.037_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2011.09.037_bb0015","first-page":"331","article-title":"Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin","volume":"66","author":"Williams","year":"1992","journal-title":"Lab Invest"},{"key":"10.1016\/j.jns.2011.09.037_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2152\/jmi.55.17","article-title":"Optimal therapy for thymoma","volume":"55","author":"Kondo","year":"2008","journal-title":"J Med Invest"},{"key":"10.1016\/j.jns.2011.09.037_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004280050044","article-title":"Pathogenesis of myasthenia gravis","volume":"430","author":"Marx","year":"1997","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jns.2011.09.037_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","article-title":"An essential role for Scurfin in CD4+ CD25+ T regulatory cells","volume":"4","author":"Khattri","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0035","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0040","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jns.2011.09.037_bb0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.jns.2011.09.037_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jns.2011.09.037_bb0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clim.2004.04.005","article-title":"Increase of circulating CD4+ CD25+ T cells in myasthenia gravis patients with stability and thymectomy","volume":"112","author":"Sun","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.0300-9475.2004.01410.x","article-title":"Circulating CD4+ CD25+ and CD4+ CD25+ T cells in myasthenia gravis and in relation to thymectomy","volume":"59","author":"Huang","year":"2004","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.51.3.364","article-title":"B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue","volume":"51","author":"Carlsen","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jns.2011.09.037_bb0070","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1084\/jem.20021294","article-title":"Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development","volume":"197","author":"Luther","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.jns.2011.09.037_bb0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.187.4.655","article-title":"B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1\/CXCR5","volume":"187","author":"Legler","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jns.2011.09.037_bb0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/eje.0.1500225","article-title":"The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases","volume":"150","author":"Aust","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jns.2011.09.037_bb0085","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood-2005-06-2383","article-title":"The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis","volume":"108","author":"Meraouna","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jns.2011.09.037_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2010.02.013","article-title":"Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia","volume":"221","author":"Shiao","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0095","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.09.037_bb0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.037_bb0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1052-3359(25)00577-0","article-title":"Histologic typing of thymoma according to the new World Health Organization classification","volume":"11","author":"Dadmanesh","year":"2001","journal-title":"Chest Surg Clin N Am"},{"key":"10.1016\/j.jns.2011.09.037_bb0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2011.09.037_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archneur.56.1.25","article-title":"Late-onset myasthenia gravis: a changing scene","volume":"56","author":"Aarli","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.09.037_bb0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2008.11.015","article-title":"The role of FoxP3+ CD4+ CD25hi Tregs in the pathogenesis of myasthenia gravis","volume":"122","author":"Zhang","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jns.2011.09.037_bb0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10875-007-9147-2","article-title":"Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy","volume":"28","author":"Fattorossi","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jns.2011.09.037_bb0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","article-title":"Inflammatory cell infiltration of tumors: Jekyll or Hyde","volume":"26","author":"Talmadge","year":"2007","journal-title":"Cancer Metastasis Rev"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11005995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11005995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:41:37Z","timestamp":1758382897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X11005995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":27,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0022510X11005995"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2011.09.037","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different molecular expression in thymoma with ocular or generalized myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2011.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}